Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 18/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8091798 | 0.93 | SLC6A9 (0.57) | SLC6A9 | |
| SCHEMBL8088699 | 0.91 | SLC6A9 (0.56) | SLC6A9 | |
| SCHEMBL8085384 | 0.90 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL13970173 | 0.90 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL13970066 | 0.90 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL13970109 | 0.87 | SLC6A9 (0.49) | SLC6A9 | |
| SCHEMBL13970180 | 0.85 | SLC6A9 (0.49) | SLC6A9 | |
| SCHEMBL13970228 | 0.83 | SLC6A9 (0.55) | SLC6A9 | |
| SCHEMBL8086612 | 0.83 | SLC6A9 (0.55) | SLC6A9 | |
| SCHEMBL8086589 | 0.82 | SLC6A9 (0.52) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030033-A1 | Novel Compounds 894 | AZI2, TPMT, AMPD2 | SLC6A9 4382/4885TAS1R3 2231/4885TAS1R1 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.